Cost-effectiveness of Denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women

Mickaël Hiligsmann; Jean-Yves Reginster

Back

Cost-effectiveness of Denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women

Conference proceeding

Peer reviewed

Cost-effectiveness of Denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women

Mickaël Hiligsmann and Jean-Yves Reginster

Osteoporosis International, 22 (Suppl.1), S112-113 (2011-03); European Congress on Osteoporosis and Osteoarthritis ECCEO11-IOF, Valencia, Spain [ES], du 23 mars 2011 au 26 mars 2011

03/2011

Abstract

Business & economic sciences

Domaines particuliers de l’économie (santé, travail, transport...)

Human health sciences

Public health, health care sciences & services

Rheumatology

Rhumatologie

Santé publique, services médicaux & soins de santé

Sciences de la santé humaine

Sciences économiques & de gestion

Special economic topics (health, labor, transportation...)

Metrics

1 Record Views

Details

Title: Cost-effectiveness of Denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women
Creators - without role: Mickaël Hiligsmann
Jean-Yves Reginster
Conference: Osteoporosis International, 22 (Suppl.1), S112-113 (2011-03); European Congress on Osteoporosis and Osteoarthritis ECCEO11-IOF, Valencia, Spain [ES], du 23 mars 2011 au 26 mars 2011
Publisher: Springer Science & Business Media B.V
Identifiers: 9952297008331
Academic Unit: King Saud University
Language: English
Resource Type: Conference proceeding